Capital Markets

A Law360 Capital Markets Group of the Year in 2021

Fenwick is a market leader and one of the premier law firms in the United States for advising technology and life sciences companies, as well as the top global investment banks, on initial public offerings and a broad range of equity and debt transactions. We guide clients through traditional IPOs as well as innovative pathways to the public markets, including special purpose acquisition company (SPAC) transactions, direct listings and reverse mergers. We know the ins and outs of the public offering process and life as a public company, and our legal advice is designed to be given in a digestible, practical manner. We deliver customized legal advice keeping in mind your business objectives and the practical realities of your business.

Our team represents investor-backed startups, high growth private companies and prominent public companies, offering deep experience across every stage of the corporate lifecycle. We collaborate closely with many of the most active investment banks, bringing market insight, practical judgment and industry specific expertise to help clients achieve successful capital markets outcomes.

As a market leader in advising technology and life sciences companies, our consistent, high volume activity places us among the world’s foremost advisors for capital markets transactions and corporate representation. In 2025 alone, Fenwick has advised as issuer or underwriter counsel on over 40% of all technology IPOs grossing over $475 million (Deal Point Data), including advising as issuer’s counsel on the largest VC-backed IPOs of 2025 (CoreWeave and Figma). Fenwick also ranks #1 for U.S. public listings by company valuation from 2012 through 2025 (according to Deal Point Data), underscoring the firm’s market leading role in guiding high growth companies to the public markets.

Fenwick’s Capital Markets practice has also been nationally ranked by Chambers USA for 18 consecutive years among the country’s top Capital Markets firms, highlighting Fenwick’s longstanding reputation for excellence and its deep experience advising high growth technology and life sciences companies. In 2024, The Legal 500 recognized Fenwick as one of the leading Capital Markets firms in the United States, and in 2021 our team was named a Capital Markets Group of the Year by Law360.

Premier Counsel for Public Companies

Our work doesn’t end at the closing of your IPO. Fenwick serves as trusted legal and business advisors to public companies, helping leadership navigate high-stakes decisions, complex board dynamics, regulatory scrutiny and investor expectations. We are in the room with boards, executives and legal teams, providing clear, real-time guidance grounded in both legal acumen and a pragmatic understanding of your business and risk profile.

We don’t view this work as limited to securities compliance—our counsel is holistic, steady, and informed by deep industry experience. Drawing on our extensive background supporting innovative public technology and life science companies, we bring pattern recognition, a calm presence and sound judgment to the moments that matter most.

Our integrated approach ensures continuity of counsel throughout the full public company lifecycle—from the initial offering through ongoing governance, disclosure, and strategic transactions—helping our clients thrive in the public markets with confidence and clarity.

Facebook (NASDAQ: FB) – Initial Public Offering, $16B (one of the largest tech listings of all time)
CoreWeave (NASDAQ: CRWV) — Initial Public Offering, $1.5B (second‑largest tech IPO since 2022)
SentinelOne (NYSE: S) — Initial Public Offering, $1.4B
Figma (NYSE: FIG) — Initial Public Offering, $1.2B
Peloton (NASDAQ: PTON) — Initial Public Offering, $1.2B
GitLab (NASDAQ: GTLB) — Initial Public Offering, $800M
Workday (NYSE: WDAY) — Initial Public Offering, $732.5M
Fitbit (NYSE: FIT) — Initial Public Offering, $732M
Remitly (NASDAQ: RELY) — Initial Public Offering, $523M
Wealthfront (NASDAQ: WLTH) — Initial Public Offering, $484M
Compass (NYSE: COMP) — Initial Public Offering, $450M
Bill.com (NYSE: BILL) — Initial Public Offering, $216M
Upwork (NASDAQ: UPWK) — Initial Public Offering, $215.2M
BitGo (NYSE: BTGO) — Initial Public Offering, $212M
Smartsheet (NYSE: SMAR) — Initial Public Offering, $175M
UserTesting (NYSE: USER) — Initial Public Offering, $140M
Alteryx (NYSE: AYX) — Initial Public Offering, $126M
Coinbase (NASDAQ: COIN) — Direct Listing on Nasdaq ($99.6B valuation at direct listing and first major crypto company to go public)
ZipRecruiter (NYSE: ZIP) — Direct Listing on NYSE ($2.0B+ valuation at direct listing)
Nextdoor (NYSE: KIND) — Business combination with Khosla Ventures Acquisition Co. II (SPAC), $4.3B
Proterra (NASDAQ: PTRA) — Business combination with ArcLight Clean Transition Corp. (SPAC), $1.6B

GeneDx Holdings Corp. (NASDAQ: WGS) — SPAC and Reverse Merger, $2.0B
BioAge Labs (NASDAQ: BIOA) — Upsized Initial Public Offering + concurrent private placement, $238M
Chinook Therapeutics (NASDAQ: KDNY) — SPAC and Reverse Merger, $225M
Third Harmonic Bio (NASDAQ: THRD) —Upsized Initial Public Offering, $213M
Nurix Therapeutics (NASDAQ: NRIX) — Initial Public Offering, $209M
DICE Therapeutics (NASDAQ: DICE) — Initial Public Offering, $204M
Day One Biopharmaceuticals (NASDAQ: DAWN) — Initial Public Offering, $184M
Arcutis Biotherapeutics (NASDAQ: ARQT) — Initial Public Offering, $183.3M
Prelude Therapeutics (NASDAQ: PRLD) — Initial Public Offering, $181.9M
Stoke Therapeutics (NASDAQ: STOK) — Initial Public Offering, $163M
Passage Bio (NASDAQ: PASG) — Initial Public Offering, $154M
Maze Therapeutics (NASDAQ: MAZE) — Upsized Initial Public Offering, $140M
Morphic Therapeutic (NASDAQ: MORF) — Initial Public Offering, $103.5M
Elevation Oncology (NASDAQ: ELEV) — Initial Public Offering, $100M
Sutro Biopharma (NASDAQ: STRO) — Initial Public Offering, $98M
Graybug Vision (NASDAQ: GRAY) — Initial Public Offering, $90M
AnaptysBio (NASDAQ: ANAB) — Initial Public Offering, $86M
Impel NeuroPharma (NASDAQ: IMPL) — Initial Public Offering, $80M
Achieve Life Sciences (NASDAQ: ACHV) — Initial Public Offering, $45M